Ensoma

Boston, MA · Founded 2019 · CIK 0001846902 · Biotech · Private

in vivo hematopoietic stem cell engineering platform combining delivery system and gene engineering toolkit

ensoma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$120M
2 Form D · Jan 2023
45 months since last filing
Contracts
—
No federal contracts on record
Patents
24
0 granted · 24 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$40,549,910
Private capital raisedForm D · SEC$79,000,469
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2808TRIM-EDICINE INC——
2809Orna Therapeutics Holdings, LLC—$121M
2810Edgewise Therapeutics—$120M
2811Ensoma—$120M
2812A2 Biotherapeutics—$119M
2813Interius BioTherapeutics—$118M
2814TAMBO, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Mark ChinDirector
  • Kouki HarasakiDirector
  • Stephen KnightDirector
  • Emile NuwaysirDirector · Executive Officer
  • Kush ParmarDirector · Executive Officer
  • Albert SeymourDirector
  • Nihal SinhaDirector
  • Paula SoteropoulosDirector

Patents

USPTO · 0 granted of 24
  • Adenoviral Helper Vectorsapplication
  • Adenoviral Gene Therapy Vectorsapplication
  • Dosing Regimens For The Mobilization Of Hematopoietic Stem Cellsapplication
  • Dosing Regimens For The Mobilization Of Hematopoietic Stem And Progenitor Cellsapplication
  • Modification Of Epor-encoding Nucleic Acidsapplication
  • Adenoviral Serotype 35 Helper Vectorsapplication
  • Dosing Regimens For Hematopoietic Stem Cell Mobilization For Stem Cell Transplants In Multiple Myeloma Patientsapplication
  • Adenoviral Gene Therapy Vectorsapplication
  • Adenoviral Gene Therapy Vectors And Methods Of Use Thereofapplication
  • Constructs For Multi-lineage Expression Of Therapeutic Agentsapplication
  • Dosing Regimens For The Mobilization Of Hematopoietic Stem Cellsapplication
  • Adenoviral Helper Vectorsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.